B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...

The CHMP has recommended Rybrevant (amivantamab) for use alongside carboplatin and pemetrexed chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR exon ...

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...

With recent full approval in both first-line and second-line MET exon 14 skipping alteration lung cancer, savolitinib remains one of the best-in-class medicines. A registration-intent study in MET ...

Eligible patients from 50 hospitals across China were histologically or cytologically confirmed by a central laboratory as having NSCLC with EGFR exon 21 Leu858Arg mutation or exon 19 deletion.

Most EGFR-mutated NSCLCs show some level of HER3 ... with this form of cancer who have specific EGFR mutations, namely exon 19 deletion or L858R mutation.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial r ...

Shirish M. Gadgeel, MD, discussed long-term data from the MARIPOSA trial of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer. The combination of lazertinib (Lazcluze) and ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed ...